Breast Oncology Clinical Nurse Specialist (CNS)

The CNS is the patient's key worker will manage their own clinical caseload, providing highly specialist nursing input and continuity of care to patients at each stage of the pathway (diagnosis, treatment, surveillance and longer term follow up).

The successful applicant will be an experienced cancer nurse with proven clinical skills and knowledge in the field of cancer and a commitment to prividing the highest standard of care to Breast Cancer patients. We are looking for an individual with strong communication skills who has the ability to impart complex information to patients, relatives and carers., You should be able to demonstrate an understanding of the physical and psychological challenges faced by this group of patients. You will also be adaptable to the evolving needs of our patients and be willing to participate in service development that reflects the changing ways care can be delivered.

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research. We provide first-class acute and specialist services across eight sites:

• University College Hospital (incorporating the Elizabeth Garrett Anderson Wing), We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.
We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.